Biomage

What Biomage does

Biomage is a UK-based (Edinburgh-registered, Glasgow-operating) software company founded in 2019-2020 that built and hosted Cellenics®, an open-source cloud-based analytics platform for single-cell RNA sequencing (scRNA-seq) data developed at Harvard Medical School under the scientific supervision of Prof. Peter Kharchenko. The platform provides biologists with a no-code workflow from count matrices to publication-ready figures, integrating automated QC filtering (doublet scoring, empty-droplet detection, mitochondrial content), batch-effect correction (Harmony, Seurat v4, fast MNN), automated cell-type annotation (ScType), and trajectory/differential expression/pathway analysis. It supports multiple scRNA-seq technologies including 10x Genomics Chromium, BD Rhapsody, and Parse Biosciences Evercode.

The company operates a tiered monetization model: (1) a free cloud community instance at scp.biomage.net for academic researchers with datasets up to 500,000 cells, which functions as a product-led growth and lead-generation layer; (2) bespoke private deployments for biotech and pharmaceutical customers, integrating Cellenics with customer data infrastructure, providing technical support, tailored training, and custom feature development; and (3) a $450 self-paced online training course offered via courses.biomage.net. Customer segments named include academic researchers (Harvard, Oxford, UVA, Albany, UCSF, Toronto, Glasgow, Wellcome Sanger Institute), biotech firms, and large pharmaceutical companies. The company also runs a co-marketing motion with instrument vendors (10x Genomics, Singleron Biotechnologies) and an active user community forum at community.biomage.net.

Biomage was acquired by Parse Biosciences on January 16, 2024. Following the acquisition, the Biomage-hosted Cellenics instance was rebranded as Trailmaker and integrated into Parse's commercial offering, combining Parse's Evercode combinatorial barcoding wet-lab technology with Cellenics/Trailmaker analytics. All Biomage staff were integrated into Parse's team, and the platform is offered free for academic researchers and Parse customers, signaling a strategic pivot from independent freemium-with-enterprise-services to OEM/instrument-bundled commercialization.

Name

Biomage

Legal name

Biomage Ltd.

Website

https://biomage.net

Company type

Private

Founded year

2020

Operating status

Acquired

Headcount range

11–50 employees

Short description

Biomage provides a cloud-based, no-code analytics platform (Cellenics, now Trailmaker) for single-cell RNA sequencing data, serving academic researchers and biotech/pharma enterprises, and was acquired by Parse Biosciences in January 2024.

Ownership category

akta.pro rank

Product category

Bioinformatics Software / Single-Cell Genomics Analytics

NAICS

Computer Systems Design and Related Services (54151), Computer Systems Design and Related Services (5415)

SIC

Services-Prepackaged Software (7372), Services-Computer Processing & Data Preparation (7374)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Single-cell RNA sequencing
• ScRNA-seq data analysis
• No-code bioinformatics
• Cloud genomics platform
• Biomarker discovery

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Academic Freemium: Free access to community instance of Cellenics® for academic researchers with small/medium datasets up to 500,000 cells. Serves as lead generation and community building for future commercial adoption.
2. Enterprise Private Deployment & Support: Private and secure deployment of Cellenics® on enterprise infrastructure with technical support, maintenance, access to new features, and tailored training for bioinformaticians, data scientists, and wet-lab biologists. Also includes feature development for customized data analysis solutions.
3. Online Training Course: Self-paced online course 'Mastering Single Cell RNA-seq Data Analysis with Cellenics®' priced at $450 USD. Includes video lessons, PDF materials, 30-minute personalized bioinformatician session, and optional live group sessions.
4. Acquisition by Parse Biosciences: Biomage was acquired by Parse Biosciences in January 2024. Parse customers will have access to Cellenics® rebranded as Trailmaker, combining wet-lab and data analytics technologies.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Biomage provides a cloud-based, no-code, open-source platform (Cellenics, rebranded as Trailmaker following the January 2024 Parse Biosciences acquisition) for analyzing single-cell RNA sequencing data. The platform enables biologists to perform end-to-end scRNA-seq analysis — quality control, doublet detection, dimensionality reduction, clustering, cell-type annotation, data integration, differential expression, pathway analysis, and trajectory inference — without writing R or Python code. It serves academic researchers through a free hosted Community Instance and biopharma customers through private enterprise deployments with full support and custom development.

Product overview

Biomage provides a product portfolio centered on Cellenics, an open-source scRNA-seq data analysis platform developed at Harvard Medical School. Cellenics offers a cloud-based, user-friendly interface enabling biologists to process, analyze, and visualize single-cell RNA sequencing data without coding. The core Cellenics product was rebranded as Trailmaker following Biomage's acquisition by Parse Biosciences in January 2024. Biomage offers tiered access: a free community cloud instance for academic researchers (up to 500,000 cells), a paid private deployment service for commercial partners requiring secure on-infrastructure installation, and a comprehensive online training course. Key integrated capabilities include automated data processing pipelines, ScType cell type annotation, trajectory analysis, and pathway analysis via external databases. The platform supports multiple scRNA-seq technologies including 10x Genomics, BD Rhapsody, and Parse Biosciences formats.

Differentiator

Problem solved

Functional benefit

Brands

• Cellenics®: An open-source analytics tool for single-cell RNA sequencing data hosted by Biomage, developed at Harvard Medical School.

Products and services

• Cellenics

Quantifiable outcome

• Reduces time from count matrices to publication-ready figures to just a few hours
• +1 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability8 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Harvard Medical SchoolcoreStrategic or Co-development PartnerCellenics® was originally developed at Harvard Medical School under scientific supervision of Prof. Peter Kharchenko and administrative supervision of the Department of Biomedical Informatics. Biomage provided services for design and development of Cellenics®.
• 10x GenomicsminorGTM or Marketing Partner10x Genomics sponsored workshops and events. Biomage team led workshops in collaboration with 10x Genomics, including virtual workshop on July 7, 2022. 10x Genomics organized London Multiomics Discovery Symposium where Biomage participated.
• Singleron BiotechnologiesminorGTM or Marketing PartnerSingleron Biotechnologies co-hosted a virtual webinar with Biomage on August 2, 2022 to introduce the Cellenics® platform to Singleron users.
• University of OxfordminorStrategic or Co-development PartnerVirtual workshop on December 7, 2021 introduced Cellenics® to University of Oxford staff and students with introduction by Prof. Peter Kharchenko.
• University of GlasgowminorStrategic or Co-development PartnerCo-hosted workshop with Glasgow Polyomics on November 12, 2021 featuring Prof. Peter Kharchenko and hands-on Cellenics® demonstration.
• Harvard Medical School (HMS)minorStrategic or Co-development PartnerVirtual workshop at Harvard Medical School on September 20, 2021 with introduction by Prof. Peter Kharchenko and hands-on tutorial.
• American Dental Association Science & Research InstituteminorStrategic or Co-development PartnerDr. Quinn T. Easter and Dr. Kevin Matthew Byrd from ADA Science & Research Institute used Cellenics® for periodontal research, producing the first integrated periodontal meta-atlas of single-cell RNA sequencing data.
• University of TorontominorStrategic or Co-development PartnerVirtual workshop for University of Toronto, Sunnybrook Health Sciences Centre, University Health Network (UHN), and Hospital for Sick Children (SickKids) on March 24, 2022.
• Turku Bioscience Centre Single-Cell Omics Core FacilityminorStrategic or Co-development PartnerVirtual workshop collaboration on September 15, 2022 for single-cell RNA-seq data analysis training using Cellenics®.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Qlucore: Qlucore provides interactive, visualization-driven omics analysis software (Qlucore Omics Explorer) used by biologists and clinicians. It competes with Cellenics/Trailmaker for non-coding biomedical researchers needing guided, GUI-based exploration of complex omics datasets.
• Partek (Partek Flow): Partek Flow is a commercially established point-and-click bioinformatics suite for single-cell RNA-seq, bulk RNA-seq, and multi-omics analysis. It competes head-to-head with Cellenics/Trailmaker for non-coding biologists and pharma research teams needing no-code workflows.
• SeqGeq (FlowJo / BD Biosciences): SeqGeq is BD's scRNA-seq analysis platform extending the FlowJo brand into single-cell workflows. It directly competes with Cellenics on no-code single-cell analysis for academic and translational researchers using BD Rhapsody data.
• BioTuring: BioTuring offers BBrowser, a cloud-based, no-code single-cell RNA-seq analysis platform aimed at biologists. It is a direct peer to Cellenics/Trailmaker on user-friendly, web-delivered scRNA-seq analysis with similar visualization and integration capabilities.

Broad incumbents

• DNAnexus: DNAnexus is a cloud bioinformatics platform serving pharma and clinical genomics customers with secure, scalable data analysis pipelines. It overlaps with Biomage's enterprise private-deployment positioning for regulated pharma customers needing integrated cloud analysis infrastructure.
• Velsera (formerly Seven Bridges Genomics): Velsera operates a secure, cloud-based platform for multi-omics data analysis serving pharma, clinical research, and population genomics customers. Comparable to Biomage on the enterprise private-deployment positioning for regulated and large-scale data analysis needs.
• Illumina (BaseSpace / DRAGEN): Illumina is the dominant sequencing platform vendor and offers BaseSpace plus DRAGEN analysis pipelines for downstream interpretation. It overlaps with Biomage on bundled sequencing-to-analysis workflows and competes at the high end of pharma translational research customers.
• 10x Genomics: 10x Genomics is the dominant single-cell instrument vendor (Chromium) and offers Loupe Browser, its own scRNA-seq visualization and analysis tool. It is comparable to Biomage because it both supplies the upstream data format that Cellenics ingests and competes directly in the downstream analysis layer.

Emerging players

• Rosalind (OnRamp Bioinformatics): Rosalind is a cloud-based, collaborative bioinformatics platform for genomics and multi-omics analysis targeted at biologists and core facilities. It competes with Biomage on no-code omics workflows and is comparable on the academic-to-enterprise adoption model.
• Aivia (DRVision Technologies): Aivia is an AI-powered visualization and analysis platform for image-based and single-cell omics data. It is comparable to Biomage on interactive, GUI-driven exploratory analysis for biologists, with a partial overlap in single-cell and spatial workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/BiomageLtd
• LinkedInlinkedin.com/company/biomage-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomage